Fig. 1From: Safety and efficacy of guanfacine extended-release in adults with attention-deficit/hyperactivity disorder: an open-label, long-term, phase 3 extension studyPatient disposition. DBT: double-blind trial; GXR, guanfacine extended-releaseBack to article page